Pharmazz Inc. submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates

Source :: Plus Company Updates. February 7, 2022
Publication Year :: 2022
Abstract: WILLOWBROOK: Pharmazz, Inc. has issued the following news release: Pharmazz, Inc. ('Pharmazz'), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today announced [...]

Subjects :: Stroke (Disease) -- Drug therapy
Encephalopathy -- Drug therapy
Clinical trials
Infants (Newborn) -- Drug therapy
General interest
News, opinion and commentary

Tools